Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy.

摘要: Hypoxia is a known feature of aggressive solid tumors as well critical hallmark the niche in hematologic malignances. associated with insufficient response to standard therapy, resulting disease progression and curtailed patients' survival through maintenance noncycling cancer stem-like cells. A better understanding mechanisms signaling pathways induced by hypoxia essential overcoming these effects. Recent findings demonstrate that bone marrow setting malignancies highly hypoxic, expansion hypoxic niches stabilization oncogenic hypoxia-inducible factor-1alpha (HIF1α). Solid have also been shown harbor areas, maintaining cells via HIF1α pathway. Developing new strategies for targeting has become crucial approach modern therapy. The number preclinical clinical trials low-oxygen tumor compartments or hypoxia-activated prodrugs increasing. This review discusses development their applicability treating both tumors. Clin Cancer Res; 23(10); 2382-90. ©2017 AACR.